Phase II trial of mitoxantrone and cisplatin in advanced non-small-cell lung cancer

Lynn G. Feun, Niramol Savaraj, Jeanine Solomon, Amy Liebmann, Judith Hurley

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Because in vitro data suggest that mitoxantrone may be synergistic with cisplatin, a Phase II trial of mitoxantrone and cisplatin was conducted in patients with advanced or metastatic non-small-cell lung cancer (NSLC). Twenty-four patients were evaluable for response. Toxicity was tolerable. Partial responses occurred in three patients (13%). This response rate is similar to that reported for cisplatin alone in NSLC. Mitoxantrone did not improve the response rate when combined with cisplatin for patients with advanced NSLC.

Original languageEnglish (US)
Pages (from-to)190-192
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume19
Issue number2
DOIs
StatePublished - Apr 1 1996

Keywords

  • Cisplatin
  • Lung cancer
  • Mitoxantrone

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II trial of mitoxantrone and cisplatin in advanced non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this